Novel Mechanism of and Therapeutic Approach for Anthracycline-Induced Cardiotoxicity (AIC)

Anthracyclines are potent chemotherapeutic agents known for their efficacy in treating various cancers via inhibition of topoisomerase II alpha (TOP2A). However, their clinical use is limited due to cardiotoxicity, primarily attributed to off-target inhibition of topoisomerase II beta (TOP2B) in cardiomyocytes. The well-accepted mechanism involves TOP2B inhibition as a key driver of this toxicity. Here, we identify a novel mechanism of anthracycline-induced cardiotoxicity (AIC) involving upregulated TOP2B expression and its direct impact on cardiomyocyte function. Our data show that doxorubicin significantly increased TOP2B protein levels in cardiomyocytes in AIC mouse model. The cardiomyocyte-specific, tamoxifen-inducible TOP2B transgenic mice exhibited pathophysiological features consistent with doxorubicin-induced cardiotoxicity, even without exposure to anthracyclines. Additionally, we discovered that TOP2B binds to SMYD1, a histone methyltransferase critical for muscle cell function. Mutations in SMYD1 are known to cause cardiomyopathy and heart failure in humans, and loss of Smyd1 in mice results in a phenotype resembling AIC. More importantly, TOP2B ASO pretreatment can succussfully prevent the AIC in TOP2B transgenic mice and AIC mouse models. Our findings reveal a novel role for TOP2B in AIC, demonstrating that its upregulation disrupts SMYD1 function in cardiomyocytes, contributing to cardiotoxicity. This study also highlights the therapeutic potential of targeting TOP2B using ASO for preventing AIC in cancer patients, offering new insights into cardioprotective strategies.

Authors

Institutions

Publication Details

Journal
Cancer Research Communications
Published
2026-05-08
DOI
https://doi.org/10.1158/2767-9764.crc-25-0511
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel Mechanism of and Therapeutic Approach for Anthracycline-Induced Cardiotoxicity (AIC)

Rohit Moudgil, Logan Shannon, Belinda Willard, Q W Wang et al.
Cancer Research Communications
Chemotherapy-induced cardiotoxicity and mitigation
article

Novel Mechanism of and Therapeutic Approach for Anthracycline-Induced Cardiotoxicity (AIC)

Rohit Moudgil, Logan Shannon, Belinda Willard, Q W Wang, Kate Stenson, Shikha Parsai, Timothy A. Chan, Josephine Chen, Mei Yin, Jianjun Zhao, Wanying Zhang, Anlin Hou, Charlie Androjna, W H Wilson Tang, E. Rene Rodriguez, Riya A. Shimpi, Christopher Nguyen, Sathyamangla V. Naga. Prasad, Tyler J. Alban, Jennifer S. Yu, Chia-Feng Liu, Jung Lin, Sadie Johnson, Yilun Sun, Eric Gu, Prerana Bangalore. Parthasarathy, Jianhong Lin, Thomas Garrett
article en

Abstract

Anthracyclines are potent chemotherapeutic agents known for their efficacy in treating various cancers via inhibition of topoisomerase II alpha (TOP2A). However, their clinical use is limited due to cardiotoxicity, primarily attributed to off-target inhibition of topoisomerase II beta (TOP2B) in cardiomyocytes. The well-accepted mechanism involves TOP2B inhibition as a key driver of this toxicity. Here, we identify a novel mechanism of anthracycline-induced cardiotoxicity (AIC) involving upregulated TOP2B expression and its direct impact on cardiomyocyte function. Our data show that doxorubicin significantly increased TOP2B protein levels in cardiomyocytes in AIC mouse model. The cardiomyocyte-specific, tamoxifen-inducible TOP2B transgenic mice exhibited pathophysiological features consistent with doxorubicin-induced cardiotoxicity, even without exposure to anthracyclines. Additionally, we discovered that TOP2B binds to SMYD1, a histone methyltransferase critical for muscle cell function. Mutations in SMYD1 are known to cause cardiomyopathy and heart failure in humans, and loss of Smyd1 in mice results in a phenotype resembling AIC. More importantly, TOP2B ASO pretreatment can succussfully prevent the AIC in TOP2B transgenic mice and AIC mouse models. Our findings reveal a novel role for TOP2B in AIC, demonstrating that its upregulation disrupts SMYD1 function in cardiomyocytes, contributing to cardiotoxicity. This study also highlights the therapeutic potential of targeting TOP2B using ASO for preventing AIC in cancer patients, offering new insights into cardioprotective strategies.

Cancer Research Communications
University of Maryland, Baltimore (US), University of Maryland Medical Center (US), Cleveland Clinic (US), Cleveland Clinic Lerner College of Medicine (US), Northeast Ohio Medical University (US)
Good health and well-being
Openalex Percentile: Top 7%
Chemotherapy-induced cardiotoxicity and mitigation
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.